

Special Issue

Dental Pulp Stem Cells (DPSCs) and Tissue Regeneration: Mechanisms Mediated by Direct, Paracrine or Autocrine Effects

Message from the Guest Editors

A new source of mesenchymal stem cells, the so-called dental-pulp-derived stem cells (DPSCs), could represent an important tool for regenerative medicine. DPSCs have also been shown to influence the angiogenesis process, for example through the release of secretory factors or by differentiating into vascular and/or perivascular cells. Given their differentiation and trans-differentiation ability towards specialized cells, when properly implanted into a microenvironment they can also be involved in the regeneration and repair of tissue damaged by traumas, degenerative diseases and pathogens. The second and maybe even more important property that could expand the horizon of regenerative medicine is related to DPSCs' immunomodulatory functions. As matter of fact, this Special Issue aim to focus on the underlying mechanism of the regenerative potential of DPSCs that could be obtained by: (1) injured tissue substitution by differentiated DPSCs and/or (2) the de novo regeneration capability of endogenous stem cells induced by stem niche remodeling mediated by DPSCs secreted factors.

Guest Editors

Prof. Dr. Simona Delle Monache

Department of Biotechnological and Applied Clinical Sciences,
University of L'Aquila, 67100 L'Aquila, Italy

Dr. Vincenzo Mattei

Laboratory of Experimental Medicine and Environmental Pathology,
Rieti, Italy

Deadline for manuscript submissions

closed (15 September 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/96177

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).